GlassScriptPhysician profile
Donald R Bergsma
NPI 1326052234
$6,752.96
in general payments reported to CMS, 2019-2025
30 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $259 · 2021: $1,022 · 2022: $1,142 · 2023: $1,237 · 2024: $1,222 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,732.21 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Mallinckrodt Hospital Products INC. | $1,049.85 | 2021-2025 | Acthar |
| Allergan, INC. | $637.49 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $538.88 | 2019-2021 | |
| Abbvie INC. | $435.44 | 2023-2025 | Durysta, Lumigan, Alphagan P |
| Ani Pharmaceuticals, INC. | $352.41 | 2022-2024 | Purified Cortrophin Gel |
| Topcon Healthcare, INC. | $199.31 | 2024-2025 | |
| Rxsight INC | $198.83 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $197.54 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $187.46 | 2022-2025 | Miebo, Envista Envy Iol, Vyzulta |
| Dompe US, INC. | $183.96 | 2021-2024 | Oxervate |
| Horizon Therapeutics Plc | $142.78 | 2021-2023 | Tepezza |
| Omeros Corporation | $135.05 | 2019-2020 | |
| Amgen INC. | $132.68 | 2024-2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $92.25 | 2022-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $79.15 | 2019-2021 | |
| Tearlab Corp | $73.75 | 2023 | Tearlab Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.63 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $56.89 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $36.50 | 2019 | |
| Shire North American Group INC | $34.56 | 2019 | |
| Iridex Corporation | $33.74 | 2021-2023 | |
| Oyster Point Pharma, INC. | $28.88 | 2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $27.80 | 2024 | Tecnis Iol |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $16.04 | 2021 | |
| Quidel Corporation | $15.66 | 2022 | |
| Masimo Corporation | $15.41 | 2021 | |
| Thea Pharma INC. | $14.53 | 2023 | |
| Lkc Technologies, INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Bergsma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.